Chardan Capital Maintains Buy Rating for Dyne Therapeutics: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Chardan Capital has reaffirmed its Buy rating on Dyne Therapeutics (NASDAQ:DYN), increasing its price target from $20.00 to $31.00. Dyne Therapeutics, a biotech company focused on genetically driven diseases, has seen its shares rise 1.02% to $26.71. The new price target suggests a potential 16.06% increase in share price.
March 08, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital maintains Buy rating on Dyne Therapeutics, raising price target to $31, indicating a potential 16.06% increase from the current price.
The reaffirmation of the Buy rating and the increase in price target by Chardan Capital are strong positive signals for Dyne Therapeutics. Given the company's focus on developing therapies for muscle disorders and the current upward trend in its share price, the raised target suggests confidence in its future performance. The potential 16.06% increase in share price is based on the new target of $31, reflecting optimism in the company's value and prospects.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100